Recent News

• 04.23.2025 - Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
• 04.23.2025 - Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
• 04.01.2025 - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.01.2025 - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.26.2025 - Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
• 03.26.2025 - Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
• 03.25.2025 - Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
• 03.25.2025 - Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
• 03.15.2025 - Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
• 03.15.2025 - Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Recent Filings

• 04.04.2025 - EFFECT Notice of Effectiveness
• 03.26.2025 - S-3 Registration statement under Securities Act of 1933
• 03.26.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 8-K Current report
• 03.17.2025 - 8-K Current report
• 03.17.2025 - EX-99.1 EX-99.1